Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c
November 8, 2017 7:07 AM ESTAmicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $9.52 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
... More